| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2010 | Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B | Huang Y.-W.; Chayama K.; Tsuge M.; Takahashi S.; Hatakeyama T.; Abe H.; Hu J.-T.; CHUN-JEN LIU ; Lai M.-Y.; DING-SHINN CHEN ; Yang S.-S.; JIA-HORNG KAO | Antiviral Therapy | 38 | 38 | |
| 1996 | Effects of growth hormone and insulin-like growth factor 1 (IGF-1) on hepatic IGF-1-mRNA, plasma IGF-1 and nitrogen excretion in gastrectomized rats with liver cirrhosis | Inaba T.; Saito H.; Fukushima R.; Hashiguchi Y.; MING-TSAN LIN ; Inoue T.; Fukatsu K.; Muto T.; Oka T.; Takenaka A.; Takahashi S.; Noguchi T. | Clinical Nutrition | 3 | 3 | |
| 2015 | On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy | Huang Y.-W.; Takahashi S.; Tsuge M.; CHI-LING CHEN ; Wang T.-C.; Abe H.; Hu J.-T.; DING-SHINN CHEN ; Yang S.-S.; Chayama K.; JIA-HORNG KAO | Antiviral Therapy | 60 | 57 | |
| 2019 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study | Burtness B.; Harrington K.J.; Greil R.; Souli?res D.; Tahara M.; de Castro G.; Jr, Psyrri A.; Bast? N.; Neupane P.; Bratland ?.; Fuereder T.; Hughes B.G.M.; Mes?a R.; Ngamphaiboon N.; Rordorf T.; Wan Ishak W.Z.; RUEY-LONG HONG ; Gonz?lez Mendoza R.; Roy A.; Zhang Y.; Gumuscu B.; Cheng J.D.; Jin F.; Rischin D.; Lerzo G.; Tatangelo M.; Varela M.; Zarba J.J.; Boyer M.; Gan H.; Gao B.; Hughes B.; Mallesara G.; Taylor A.; Burian M.; Barrios C.H.; de Castro Junior D.O.; Castro G.; Franke F.A.; Girotto G.; Lima I.P.F.; Nicolau U.R.; Pinto G.D.J.; Santos L.; Victorino A.-P.; Chua N.; Couture F.; Gregg R.; Hansen A.; Hilton J.; McCarthy J.; Soulieres D.; Ascui R.; Gonzalez P.; Villanueva L.; Torregroza M.; Zambrano A.; Holeckova P.; Kral Z.; Melichar B.; Prausova J.; Vosmik M.; Andersen M.; Gyldenkerne N.; Jurgens H.; Putnik K.; Reinikainen P.; Gruenwald V.; Laban S.; Aravantinos G.; Boukovinas I.; Georgoulias V.; Kwong D.; Al-Farhat Y.; Csoszi T.; Erfan J.; Horvai G.; Landherr L.; Remenar E.; Ruzsa A.; Szota J.; Billan S.; Gluck I.; Gutfeld O.; Popovtzer A.; Benasso M.; Bui S.; Ferrari V.; Licitra L.; Nole F.; Fujii T.; Fujimoto Y.; Hanai N.; Hara H.; Matsumoto K.; Mitsugi K.; Monden N.; Nakayama M.; Okami K.; Oridate N.; Shiga K.; Shimizu Y.; Sugasawa M.; Takahashi M.; Takahashi S.; Tanaka K.; Ueda T.; Yamaguchi H.; Yamazaki T.; Yasumatsu R.; Yokota T.; Yoshizaki T.; Kudaba I.; Stara Z.; Cheah S.K.; Aguilar Ponce J.; Gonzalez Mendoza R.; Hernandez Hernandez C.; Medina Soto F.; Buter J.; Hoeben A.; Oosting S.; Suijkerbuijk K.; Bratland A.; Brydoey M.; Alvarez R.; Mas L.; Caguioa P.; Querol J.; Regala E.E.; Tamayo M.B.; Villegas E.M.; Kawecki A.; Karpenko A.; Klochikhin A.; Smolin A.; Zarubenkov O.; Goh B.C.; Cohen G.; du Toit J.; Jordaan C.; Landers G.; Ruff P.; Szpak W.; Tabane N.; Brana I.; Iglesias Docampo L.; Lavernia J.; Mesia R.; Abel E.; Muratidu V.; Nielsen N.; Cristina V.; Rothschild S.; Wang H.-M.; Yang M.-H.; Yeh S.-P.; Yen C.-J.; Soparattanapaisarn N.; Sriuranpong V.; Aksoy S.; Cicin I.; Ekenel M.; Harputluoglu H.; Ozyilkan O.; Harrington K.; Agarwala S.; Ali H.; Alter R.; Anderson D.; Bruce J.; Campbell N.; Conde M.; Deeken J.; Edenfield W.; Feldman L.; Gaughan E.; Goueli B.; Halmos B.; Hegde U.; Hunis B.; Jotte R.; Karnad A.; Khan S.; Laudi N.; Laux D.; Martincic D.; McCune S.; McGaughey D.; Misiukiewicz K.; Mulford D.; Nadler E.; Nunnink J.; Ohr J.; O'Malley M.; Patson B.; Paul D.; Popa E.; Powell S.; Redman R.; Rella V.; Rocha Lima C.; Sivapiragasam A.; Su Y.; Sukari A.; Wong S.; Yilmaz E.; Yorio J. | The Lancet | 1460 | 1342 | |
| 2021 | Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with HER2-expressing advanced solid tumors | Takahashi S.; Karayama M.; Takahashi M.; Watanabe J.; Minami H.; Yamamoto N.; Kinoshita I.; CHIA-CHI LIN ; Im Y.-H.; Achiwa I.; Kamiyama E.; Okuda Y.; Lee C.; Bang Y.-J. | Clinical Cancer Research | 9 | 9 | |
| 2017 | A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141 | Kiyota N.; Hasegawa Y.; Takahashi S.; Yokota T.; Yen C.-J.; Iwae S.; Shimizu Y.; RUEY-LONG HONG ; Goto M.; Kang J.-H.; Sum Kenneth Li W.; Ferris R.L.; Gillison M.; Namba Y.; Monga M.; Lynch M.; Tahara M. | Oral Oncology | 75 | 65 | |
| 2020 | Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) | Yen C.-J.; Kiyota N.; Hanai N.; Takahashi S.; Yokota T.; Iwae S.; Shimizu Y.; RUEY-LONG HONG ; Goto M.; Kang J.-H.; Li W.S.K.; Ferris R.L.; Gillison M.; Endo T.; Jayaprakash V.; Tahara M. | Head and Neck | 21 | 18 |
